Cardiff Oncology (STU:XE7C) ROCE % : -54.25% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Cardiff Oncology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cardiff Oncology's annualized ROCE % for the quarter that ended in Dec. 2023 was -54.25%.

Cardiff Oncology ROCE % Historical Data

The historical data trend for Cardiff Oncology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology ROCE % Chart

Cardiff Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-170.18

-28.04

-21.99

-32.92

-49.69

Cardiff Oncology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-32.41	-46.37	-51.98	-52.00	-54.25

Cardiff Oncology ROCE % Calculation

Cardiff Oncology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-41.643	/	( ( (109.684 - 7.371)	+	(74.861 - 9.573) )	/ 2 )
	=	-41.643	/	( (102.313	+	65.288)	/ 2 )
	=	-41.643	/	83.8005
	=	-49.69 %

Cardiff Oncology's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-37.896	/	( ( (82.88 - 8.45)	+	(74.861 - 9.573) )	/ 2 )
	=	-37.896	/	( ( 74.43	+	65.288 )	/ 2 )
	=	-37.896	/	69.859
	=	-54.25 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Cardiff Oncology (STU:XE7C) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cardiff Oncology ROCE % Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology (STU:XE7C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (STU:XE7C) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CRDF:USA XE7C:Germany

Address

11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website

https://www.cardiffoncology.com

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Cardiff Oncology (STU:XE7C) Headlines

No Headlines